GRI Bio, Inc. (NASDAQ:GRI) Short Interest Update

GRI Bio, Inc. (NASDAQ:GRI) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 438,400 shares, an increase of 15,557.1% from the August 15th total of 2,800 shares. Approximately 15.0% of the company’s shares are sold short. Based on an average daily volume of 602,900 shares, the days-to-cover ratio is presently 0.7 days.

Hedge Funds Weigh In On GRI Bio

An institutional investor recently bought a new position in GRI Bio stock. Armistice Capital LLC acquired a new stake in shares of GRI Bio, Inc. (NASDAQ:GRI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned 9.23% of GRI Bio at the end of the most recent quarter. Institutional investors own 33.95% of the company’s stock.

GRI Bio Price Performance

Shares of NASDAQ GRI opened at 0.50 on Friday. The firm has a fifty day simple moving average of 0.88 and a 200 day simple moving average of 4.40. GRI Bio has a twelve month low of 0.40 and a twelve month high of 161.98.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings data on Tuesday, August 13th. The company reported -4.92 earnings per share (EPS) for the quarter.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.